Literature DB >> 22627901

Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth.

Kimberly A Yonkers1, Errol R Norwitz, Megan V Smith, Charles J Lockwood, Nathan Gotman, Edward Luchansky, Haiqun Lin, Kathleen Belanger.   

Abstract

BACKGROUND: Major depressive disorder and the use of serotonin reuptake inhibitors (SRIs) in pregnancy have been associated with preterm birth. Studies that have attempted to separate effects of illness from treatment have been inconclusive. We sought to explore the separate effects of SRI use and major depressive episodes in pregnancy on risk of preterm birth.
METHODS: We conducted a prospective cohort study of 2793 pregnant women, oversampled for a recent episode of major depression or use of an SRI. We extracted data on birth outcomes from hospital charts and used binary logistic regression to model preterm birth (<37 weeks' gestation). We used ordered logistic regression to model early (<34 weeks' gestation) or late (34-36 weeks) preterm birth, and we used nominal logistic regression to model preterm birth antecedents (spontaneous preterm labor/preterm premature rupture of membranes/preterm for medical indications/term).
RESULTS: Use of an SRI, both with (odds ratio = 2.1 [95% confidence interval = 1.0-4.6]) and without (1.6 [1.0-2.5]) a major depressive episode, was associated with preterm birth. A major depressive episode without SRI use (1.2 [0.68-2.1]) had no clear effect on preterm birth risk. None of these exposures was associated with early preterm birth. Use of SRIs in pregnancy was associated with increases in spontaneous but not medically indicated preterm birth.
CONCLUSIONS: SRI use increased risk of preterm birth. Although the effect of a major depressive episode alone was unclear, symptomatic women undergoing antidepressant treatment had elevated risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627901      PMCID: PMC3415566          DOI: 10.1097/EDE.0b013e31825838e9

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  39 in total

1.  Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth.

Authors:  Rita Suri; Lori Altshuler; Gerhard Hellemann; Vivien K Burt; Ana Aquino; Jim Mintz
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

2.  Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

Authors:  Tim F Oberlander; William Warburton; Shaila Misri; Jaafar Aghajanian; Clyde Hertzman
Journal:  Arch Gen Psychiatry       Date:  2006-08

3.  Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.

Authors:  N A Kulin; A Pastuszak; S R Sage; B Schick-Boschetto; G Spivey; M Feldkamp; K Ormond; D Matsui; A K Stein-Schechman; L Cook; J Brochu; M Rieder; G Koren
Journal:  JAMA       Date:  1998-02-25       Impact factor: 56.272

4.  Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey.

Authors:  R C Kessler; C B Nelson; K A McGonagle; J Liu; M Swartz; D G Blazer
Journal:  Br J Psychiatry Suppl       Date:  1996-06

5.  Prepregnancy health status and the risk of preterm delivery.

Authors:  Jennifer S Haas; Elena Fuentes-Afflick; Anita L Stewart; Rebecca A Jackson; Mitzi L Dean; Phyllis Brawarsky; Gabriel J Escobar
Journal:  Arch Pediatr Adolesc Med       Date:  2005-01

6.  Risks associated with selective serotonin reuptake inhibitors in pregnancy.

Authors:  Heli Malm; Timo Klaukka; Pertti J Neuvonen
Journal:  Obstet Gynecol       Date:  2005-12       Impact factor: 7.661

7.  Selective serotonin reuptake inhibitors and adverse pregnancy outcomes.

Authors:  Shi Wu Wen; Qiuying Yang; Peter Garner; William Fraser; Olufemi Olatunbosun; Carl Nimrod; Mark Walker
Journal:  Am J Obstet Gynecol       Date:  2006-04       Impact factor: 8.661

8.  Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care.

Authors:  Jacques Dayan; Christian Creveuil; Maureen N Marks; Sue Conroy; Michel Herlicoviez; Michel Dreyfus; Sylvie Tordjman
Journal:  Psychosom Med       Date:  2006-11-01       Impact factor: 4.312

Review 9.  Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy.

Authors:  Robert L Davis; David Rubanowice; Heather McPhillips; Marsha A Raebel; Susan E Andrade; David Smith; Marianne Ulcickas Yood; Richard Platt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-10       Impact factor: 2.890

10.  Birth outcomes in pregnant women taking fluoxetine.

Authors:  C D Chambers; K A Johnson; L M Dick; R J Felix; K L Jones
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

View more
  32 in total

1.  Clinical correlates of prescription opioid analgesic use in pregnancy.

Authors:  Megan V Smith; Darce Costello; Kimberly A Yonkers
Journal:  Matern Child Health J       Date:  2015-03

2.  Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data.

Authors:  Sonja A Swanson; Sonia Hernandez-Diaz; Kristin Palmsten; Helen Mogun; Mark Olfson; Krista F Huybrechts
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-06-04       Impact factor: 2.890

Review 3.  Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise.

Authors:  Tamar L Gur; Deborah R Kim; C Neill Epperson
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

4.  Risk for Maternal Depressive Symptoms and Perceived Stress by Ethnicities in Canada: From Pregnancy Through the Preschool Years.

Authors:  Christoffer Dharma; Diana L Lefebvre; Zihang Lu; Wendy Y W Lou; Allan B Becker; Piush J Mandhane; Stuart E Turvey; Theo J Moraes; Meghan B Azad; Edith Chen; Susan J Elliott; Anita L Kozyrskyj; Malcolm R Sears; Padmaja Subbarao
Journal:  Can J Psychiatry       Date:  2018-08-01       Impact factor: 4.356

Review 5.  Selective serotonin reuptake inhibitors and pregnancy: A review of maternal, fetal and neonatal risks and benefits.

Authors:  Zbigniew Marchocki; Noirin E Russell; Keelin O' Donoghue
Journal:  Obstet Med       Date:  2013-08-08

Review 6.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

7.  A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight.

Authors:  Hsiang Huang; Shane Coleman; Jeffrey A Bridge; Kimberly Yonkers; Wayne Katon
Journal:  Gen Hosp Psychiatry       Date:  2013-10-02       Impact factor: 3.238

8.  Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes.

Authors:  Kimberly Ann Yonkers; Kathryn Gilstad-Hayden; Ariadna Forray; Heather S Lipkind
Journal:  JAMA Psychiatry       Date:  2017-11-01       Impact factor: 21.596

9.  Prenatal Primary Prevention of Mental Illness by Micronutrient Supplements in Pregnancy.

Authors:  Robert Freedman; Sharon K Hunter; M Camille Hoffman
Journal:  Am J Psychiatry       Date:  2018-03-21       Impact factor: 18.112

10.  Pregnant women screening positive for depressive symptoms at 24-28 weeks may have increased risk of preterm birth but more precise research is needed.

Authors:  Eynav Elgavish Accortt; Christine Dunkel Schetter
Journal:  Evid Based Nurs       Date:  2013-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.